Effect of Dexamethasone on Migraine Headache

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by Shiraz University of Medical Sciences.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Shiraz University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00733382
First received: August 11, 2008
Last updated: NA
Last verified: August 2008
History: No changes posted

August 11, 2008
August 11, 2008
February 2008
December 2008   (final data collection date for primary outcome measure)
to evaluate the efficacy of dexamethazone in abortive therapy of migraine attack and prevent of recurrence [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Dexamethasone on Migraine Headache
The Effect of Dexamethasone in the Attack of Migraine Headache and to Prevent of Its Relapse After Discharge From Emergency Department: a Randomized, Double-Blind, Controlled Trial.

Dexamethasone is a safe and cheap abortive therapy for migraine headache. The effect of it is never evaluate and not correlate with the effect of popular anti migraine medication such as dihydroergotamine. The investigators proposal is to compare its effect with dihydroergotamine.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Migraine Headache
Drug: dexamethazone
injection form, 8 miligram, injected once
  • Experimental: 1
    Intervention: Drug: dexamethazone
  • Active Comparator: 2
    Intervention: Drug: dexamethazone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
August 2009
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Migraine attack according to international headache society criteria
  2. Migraine without aura; at least 5 attack with mean duration of 4 to 72 hours and 2 of following:

    • Unilateral
    • Pulsatile
    • Severe enough to impair daily activity
    • Aggravate with walking and climbing, also 1 of following:

      • Nausea and or vomiting
      • Photophobia and phonophobia, and not contributed to other headache.
  3. Migraine with aura; at least 2 attacks with 3 of following:

    • One reversible aura
    • Aura became apparent at least in 4 minutes
    • Aura not lasting more than 60 minutes
    • Headache develops in less than 60 minutes after aura

Exclusion Criteria:

  1. Hypertension
  2. Ischemic heart disease
  3. Basilar migraine with sign and symptoms such as:

    • Diplopia
    • Ataxia
    • Dysarthria
    • Dysphagia
    • Weakness
    • Sensory disorder
    • Drowsiness
  4. Peripheral vascular disease
  5. Sepsis
  6. Age more than 40 and less than 15 year old
  7. Pregnancy
  8. Use of triptans and ergots derivatives in past 24 hours
Both
15 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
NCT00733382
212110
No
Reza Nemati/research manager of neurology department, Shiraz university of medical sciences
Shiraz University of Medical Sciences
Not Provided
Not Provided
Shiraz University of Medical Sciences
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP